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Abstract
Background: Various techniques, including portal vein embolization (PVE), contralateral portal vein
ligation (PVL) and associating liver partition and portal vein ligation (ALPPS), are being used to aug-
ment the future liver remnant (FLR) volume in preparation for a major hepatectomy. The present study
aims to survey and document the availability, variation, utilization and attitudes toward these tech-
niques across centres in North and South America.
Methods: A descriptive, 20-question survey was developed and internally validated with expert
review. The survey was distributed to 115 centres in North and South America.
Results: Of the 115 centres, 54 institutions (47%) returned the surveys. Regarding the question of
which modality was most likely to produce adequate hypertrophy, the respondents were equally dis-
tributed (ALPPS, 37%; PVE, 35%; equal, 22%). The procedure that respondents judged the safest to
achieve liver hypertrophy was PVE (82%). Institutions with capability to extended PVE to segment IV
rated the likelihood of PVE technical success (6.2 versus 8.5, P = 0.012) and likelihood of subsequent
hypertrophy (5.6 versus 7.8, P = 0.011) higher than institutions without this capability. Although the use
of modern embolic materials was associated with a likelihood of successful PVE (P = 0.032), only 49%
of respondents who performed PVE used embolic microspheres.
Conclusions: There exists significant variability in utilization of and attitudes towards the available
techniques for FLR volume augmentation. Penetration of best practice techniques for PVE is lacking,
and may be contributing towards disappointment with PVE efficacy, potentially motivating the utiliza-
tion of the riskier ALPPS procedure.
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Introduction
The ability to modulate the volume of the future liver remnant
(FLR) is now a core component of oncological hepatobiliary
surgical practice. Historically, the mechanisms used to induce
FLR hypertrophy have included contralateral portal vein liga-
tion (PVL) and portal vein embolization (PVE).1 In 2012, the
novel associating liver partition and portal vein ligation
(ALPPS) procedure was introduced as an alternative short-
interval two-stage procedure for FLR hypertrophy and liver
tumour resection.2 Early ALPPS series demonstrated the ability
to produce rapid and dramatic FLR growth in many, but not
all, patients.2,3 The procedure, however, has been associated
with significant morbidity and mortality rates of 9–20%.4–8
Comparative analyses have demonstrated that properly per-
formed PVE produces equivalent hypertrophy as ALPPS, even
in patients with very small FLR volumes (defined as FLR/body
weight < 0.5).9 Although ALPPS may be able to generate ade-
quate hypertrophy in a shorter time interval than PVE, facilitat-
ing a higher rate of second operation completion, it has become
clear that this rapid hypertrophy does not always correlate with
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adequate liver function.3 Furthermore, longer-term outcomes
are demonstrating high recurrence rates and inferior survivals
particularly in patients with colorectal liver metastases.10
Given the safety issues surrounding the procedure, it has
become important to understand the motivators for transition-
ing practice from PVE to ALPPS on a centre-by-centre basis.
Review of the literature identifies multiple publications that site
dissatisfaction with PVE as a motivator for attempting AL-
PPS.11–14 Further inquiry has determined that some of the rea-
sons for the disappointing PVE results may include relationship
dynamics between surgeons and interventional radiologists,
technical inability to occlude portal branches, an inability or lack
of time to extend a right PVE to segment IV, and the use of infe-
rior materials for embolization. This information yielded a
hypothesis that one motivator for attempting the ALPPS proce-
dure may be dissatisfaction with PVE outcomes, possibly owing
to a lack of access to modern PVE techniques and technologies.
This project was designed to quantitatively test this hypothesis.
Methods
A descriptive 20 question survey was developed and internally val-
idated with the administration and iterative revision by a panel of
five hepatobiliary surgeons (3 internal and 2 external) (Table 1).
The Mechanisms to Augment the Liver in North and South
America (MALINSA) survey was further edited and approved for
distribution by the research committee of the American Hepato-
Pancreato-Biliary Association (AHPBA). The survey was devel-
oped using Qualtrics software (Qualtrics LLC, Provo, UT, USA)
and distributed to institutional AHPBA representatives, typically
the chief of the liver service, via an e-mail link.
The data gathered included surgeon demographic informa-
tion, country and institution of practice, volume and type of
procedures performed by the entire HPB unit over the past year,
details regarding execution of procedures and opinions regard-
ing PVL, PVE and ALPPS procedures. Respondents whose insti-
tutions performed PVE were asked whether their institution had
the capability to include segment IV in embolizations and to rate
the likelihood of technical success (defined as the ability to com-
plete the embolization procedure as intended) and hypertrophy
of the future liver remnant on a 0–10 Likert scale. They were also
asked to specify what embolic materials were in use at their insti-
tution with non-exclusive responses that included gelfoam, cya-
noacrylate, polyvinyl alcohol and/or irregular particles, embolic
microspheres, and coils as well as the option of responding that
the surgeon ‘did not know’ what materials were being used for
PVE. Respondents whose institutions performed ALPPS were
similarly asked to rate the safety and likelihood of post-ALPPS
hypertrophy on a 0–10 Likert scale.
Given the wide variability in published outcomes, decisions
regarding the application of various techniques to augment the
FLR are made less frequently on published outcomes data, and
more frequently on the surgeon’s impression or prediction of
outcome that is coloured by various inputs including institu-
tion-specific historical and recent experience with each tech-
nique. As this survey was intended to measure the attitudes that
weigh heavily on these decisions, no specific qualifiers were
given for a definition of the term ‘safety’. Feasibility was defined
as the number of times out of 10 that the embolization was tech-
nically accomplished and the ‘likelihood of hypertrophy’ was
defined as the number of patients out of 10 treated with a partic-
ular augmentation technique who would have adequate hyper-
Table 1 The MALINSA survey questions
Questions Answers
Part I. General MALINSA Opinions
1. In your opinion, of these two
modalities, which is the most
likely to produce adequate
hypertrophy of the future liver
remnant to permit major
hepatectomy?
Surgical PVL, Percutaneous
PVE, They are equally
effective
2. In your opinion, of these three
modalities, which is the most
likely to produce adequate
hypertrophy of the future liver
remnant to permit major
hepatectomy?
Surgical PVL, Percutaneous
PVE, ALPPS, They are
equally effective
3. In your opinion, which is the
safest modality used to achieve
hypertrophy in the future
liver remnant?
Surgical PVL, Percutaneous
PVE, ALPPS, They are
equally safe
Part II. Surgical procedure volumes and outcomes
At your institution in the previous year, what was the approximate
total number of single-stage major hepatectomies performed (4 or
more liver segments removed)?
A. Single stage major hepatectomy
without augmentation?
Free numeric response
B. Single stage major
hepatectomy with previous
percutaneous PVE?
Free numeric response
C. Single stage major
hepatectomy
with previous PVL?
Free numeric response
At your institution in the previous year, what was the approximate
number of two stage hepatectomies, of the types described
below, performed?
A. Two stage without any liver
remnant augmentation?
Free numeric response
B. Two stage with
percutaneous PVE?
Free numeric response
C. Two stage with PVL at
stage 1?
Free numeric response
D. Two stage as ALPPS? Free numeric Response
1. (Displayed if D > 0) After a
patient has undergone the first
portion of an ALPPS procedure
at your institution how frequently
does the patient demonstrate
adequate hypertrophy to
permit major hepatectomy?
0-10 Likert Scale
(0 = Never, 10 = Always)
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trophy to proceed with a curative resection. Instead of asking for
the surgeon’s impression of the literature, we were asking about
the unique experience within their unit that may better explain
their treatment decisions and behaviour.
The data were anonymized to surgeon and country and
analysed as a single group. All univariate statistical analysis was
performed using the chi-squared test or Fischer’s exact test for
categorical variables or the Mann–Whitney U-test for continu-
ous variables. Continuous variables are reported as the
mean  standard deviation or median with range. All statisti-
cal analysis was performed using SPSS version 22.0.0.0 (IBM
Corp., Armonk, NY, USA).
Results
The MALINSA survey was originally distributed to 120 indi-
viduals who were designated institutional representatives from
the AHPBA member list. Of the original 120 individuals,
5 e-mail addresses were invalid, and they were excluded from
all further analysis. There were 54 responses from the 115 sur-
veyed individuals indicating a response rate of 47%. Respon-
dents were located in the United States (46.3%), Argentina
(20.4%), Canada (16.7%), Brazil (11.1%), Peru (3.7%) and
Chile (1.9%). The 25 respondents in the United States were
located in 15 different states.
When asked to judge the safest procedure for achieving liver
hypertrophy, 44 respondents (81.5%) chose PVE, 7 (13%)
chose PVL and 3 (5.6%) chose ALPPS. When asked which pro-
cedure was most likely to produce adequate hypertrophy to
permit a major hepatectomy, 20 respondents (37%) chose
ALPPS, 19 (35.2%) chose PVE, 3 (5.6%) chose PVL and 12
(22.2%) chose that all procedures were equally likely to pro-
duce adequate hypertrophy. The same question was posed
again without the inclusion of ALPPS procedures and 29
respondents (53.7%) chose PVE, 9 (16.7%) chose PVL and 16
(29.6%) responded that the remaining procedures were equally
effective (Fig. 1).
Thirty-six respondents provided information about the
number of hepatectomies performed at their institution in the
previous year. The median number of total hepatectomies per-
formed by each institution in the previous year was 51 (range
2–340). The median numbers of single stage hepatectomies
with no augmentation was 40 (range 0–220), single stage major
hepatectomies with prior PVE was 5 (range 0–60) and single
stage major hepatectomies with prior PVL was 0 (range
0–20).The median number of two stage major hepatectomies
with no prior augmentation was 1 (range 0–20), two stage
major hepatectomies with PVE was 5 (range 0–60) and major
two stage with PVL was 0 (range 0–15). There were 10 respon-
dents who reported their institution had performed at least 1
ALPPS procedure in the previous year, the median number of
ALPPS in this group was 3 (range 1–35) (Fig. 2). In respon-
dents whose institution had performed at least one ALPPS pro-
cedure, the mean value assigned to the question of ‘likelihood
to produce adequate hypertrophy to permit a major hepatec-
tomy’ on a 0–10 scale was 8.6  3.1.
Thirty-five respondents answered questions about the num-
ber of PVEs performed at their institution in the previous year,
Table 1 Continued
Questions Answers
Part III. Portal venous embolization volumes and outcomes
1. Does your institution perform
percutaneous portal vein
embolization?
Yes (Continue)/No (End)
At your institution in the previous year, what was the approximate
number of portal vein embolization procedures performed by
interventional radiology in an attempt to hypertrophy the remnant
liver?
A. Right PVE (Segment 5-8)? Free numeric response
B. Right PVE plus Segment 4
(Segment 4-8)?
Free numeric response
C. Left PVE (Segment 2-4)? Free numeric Response
2. Do your interventional
radiologists have the capability
to perform right PVE including
segment 4 branches?
Yes/No
3. At your institution, when a
patient is referred for PVE, how
frequently is interventional
radiology technically successful
(defined as the ability to
embolize the target vessels)?
0-10 Likert Scale
(0 = Never, 10 = Always)
4. At your institution, after
technically successful PVE by
interventional radiology, how
frequently does the patient
demonstrate adequate
hypertrophy to permit major
hepatectomy?
0-10 Likert Scale
(0 = Never, 10 = Always)
5. At your institution, what
embolic material do your
interventional radiologists use
for PVE? (Pick all that apply)
Gelfoam, Polyvinyl alcohol,
Microspheres, Cyanoacrylate,
Fibrin glue, Other,
I don’t know
PVE, portal vein embolization; ALPPS, associating liver partition; PVL,
portal vein ligation.
PVL
13% PVE
81%
ALPPS
6%
PVL
6%
PVE
35%
ALPPS
37%
Equally
eﬀecve
22%
(A) (B)
Figure 1 Respondents’ view of comparative safety and
hypertrophy between procedures
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PVE capabilities, the likelihood of technical success, the likeli-
hood of adequate hypertrophy to permit a major hepatectomy
and embolic materials. Thirty-four (97%) respondents reported
the capability to perform PVE and 30 (86%) reported the
capability to extend right PVE to include segment IV at their
institution. The median number of total PVEs reported in the
previous year was 10 (range 0–65). The median number of seg-
ment V through to VIII PVEs was 6 (range 0–60), segment IV
through VIII PVEs was 2 (0–30) and segment II through IV
PVEs was 0 (range 0–10). The mean value respondents
reported for a likelihood of PVE technical success on a 0–10
scale was 8.2  1.7. The mean value respondents reported for
a likelihood of achieving enough hypertrophy to permit a
major hepatectomy after PVE was 7.5  1.4. Respondents who
reported their institution had the capability to extend PVE to
segment IV were more likely to report higher values for both a
likelihood of technical success (8.5  1.5 versus 6.2  1.8,
P = 0.012) and a likelihood of adequate hypertrophy (7.8 
1.0 versus 5.6  1.9, P = 0.011) (Table 2). Institutions that
had reported performing more PVEs in the previous year also
reported higher rates of technical success (P = 0.047) (Fig. 3).
In this analysis, an annual PVE volume of 12 cases correlated
with the subjective impression of a 90% success rate.
PVE respondents were asked to report what embolic materi-
als were used at their institution and were allowed to respond
with non-exclusive answers. Nineteen (45.7%) respondents
reported the use of gelfoam, 6 (17.1%) reported the use of cya-
noacrylate, 5 (14.3%) reported the use of fibrin glue, 10
(28.6%) reported the use of polyvinyl alcohol or other irregu-
lar particles, 17 (48.6%) reported the use of microspheres, 26
(74.3%) reported the use of coils, and 4 (7.4%) respondents
did not know what embolic materials were used at their
institution. These results (excluding coils as they are commonly
used in conjunction with other embolic materials) were corre-
lated with the responses to the likelihood of successful hyper-
trophy to permit a major hepatectomy. This analysis identified
a correlation between the use of microspheres and the subjec-
tive impression of a higher likelihood of hypertrophy
(8.4  0.9 versus 7.2  1.6, P = 0.032). (Fig. 4). As well, sur-
geons who reported that they ‘did not know’ the devices used
for PVE also reported the lowest confidence in the likelihood
of hypertrophy after PVE.
Discussion
Working from the hypothesis that the impression of PVE under-
performance may be driving surgeons to attempt the higher risk
ALPPS procedure, we queried over 100 hepatobiliary surgery
centres with membership in the AHPBA. A large number of cen-
Figure 2 Relationships between the number of PVE procedures
performed and the number of ALPPS procedures performed. Each
data point represents a survey respondent. PVE, portal vein
embolization; ALPPS, associating liver partition and portal vein
ligation
Table 2 Respondents’ reported success rates at institutions with
and without segment IV embolization capabilities
Factor No Segment IV
Capabilities
(n = 5)
Segment IV
Capabilities
(n = 30)
P-value
Likelihood of technically
successful PVE
6.2  1.8 8.5  1.5 0.012
Likelihood of adequate
hypertrophy after PVE
5.6  1.9 7.8  1.0 0.011
>= 12 PVEs in
previous year
0 14 0.049
PVE, portal vein embolization.
Figure 3 Relationship between the number of portal vein
embolization procedures and likelihood of technical success. The
best fit line predicts 90% technical success when 12.5 or more
PVE procedures are performed in the previous year. PVE, portal
vein embolization
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tres actively engaged in the most complex oncological liver
resections replied. In addition, to confirming the relationship
between PVE technique and surgeon satisfaction with post-PVE
hypertrophy, multiple other important details were revealed.
One of the initial observations was that PVE and ALPPS
had a largely non-overlapping distribution, marked by several
high-volume PVE centres, several high-volume ALPPS centres
and very few simultaneously high-volume PVE/ALPPS centres.
This bi-modal distribution suggested that centres prefer one
technique or the other. Likewise, this distribution provided the
opportunity to determine the differences in the attitudes and
techniques regarding PVE between these two groups.
Along three domains, the study confirmed that a suboptimal
PVE technique was associated with surgical dissatisfaction with
its results. First, surgeons operating at centres with the ability
to perform and the desire to utilize extension of a right PVE
to segment IV were significantly more likely to rate the results
of PVE as successful. Second, the embolic materials used for
PVE were strongly associated with surgeon satisfaction with
PVE. For example, the use of Gelfoam as the embolic agent,
which frequently is defeated by recanalization of vascular struc-
tures,15,16 was associated with the lowest satisfaction with PVE.
Likewise, a lack of familiarity with an institutional PVE tech-
nique, as demonstrated by the association between the sur-
geons having no knowledge of the devices used by their
radiologists, was correlated with poor satisfaction with PVE.
The reasons for the respondent to lack this knowledge cannot
be known, but this finding may reflect weak clinical relation-
ships between surgeons and radiologists at those institutions.
Lastly, a volume–outcome relationship was demonstrated, with
a volume of greater than 12 PVE per year correlating with a
90% surgeon impression of success.
Interestingly, when asked which of the three options for FLR
augmentation can produce adequate hypertrophy to permit a
major hepatectomy, there was a near equal split between PVE,
ALPPS and equivalence between the two modalities. Given the
reported morbidity associated with early ALPPS, it is not sur-
prising that, when asked which of the techniques was safest,
81% ranked PVE as the safest modality, followed by PVL at
13% and then ALPPS in only 6%.
Given the methodology of a survey-based analysis by defini-
tion the study solicited the opinions of the respondents, who
represent a relatively small sample of all HPB surgeons. It is,
therefore, limited in its ability to, and was not intended to,
compare raw data on procedures (PVE, PVL and ALPPS) with
complication rates (safety) and per cent hypertrophy rates
(efficacy). The intentional purpose of the survey and the pro-
ject was to describe attitudes that are contributing to behav-
iours. As with all studies of this type, the results are
associations and cannot claim causation. However, previous
studies have shown that utilization of inferior PVE materials
produces inferior hypertrophy. This study corroborates this
finding, as the use of inferior PVE materials is also associated
with a surgeon’s impression of inferior results in their institu-
tion. Further linking dissatisfaction with PVE as a driver for
ALPPS development is supported by published statements
from ALPPS groups, but requires further investigation.
Conclusions
The results of this survey suggest that a suboptimal PVE tech-
nique, across multiple domains, is associated with lower surgeon
satisfaction with subsequent hypertrophic results. As this rela-
tionship may be one of the drivers for surgeons attempting the
riskier ALPPS procedure, there is an opportunity to focus on
quality improvement and collaboration between surgeons and
interventional radiologists. Recent symposia focused on an opti-
mal PVE technique convened at both the 2015 Americas He-
patopancreatobiliary Association annual meeting (March 2015,
Miami, USA) and the 1st Consensus Conference on ALPPS and
PVE (February 2015, Hamburg, Germany) demonstrate the rec-
ognition of knowledge gaps and a desire to improve care.
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